European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.

about

European perspective on the management of rheumatoid arthritis: clinical utility of tofacitinib.

Item

http://www.wikidata.org/entity/Q47338654

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

European perspective on the ma ...... inical utility of tofacitinib.

@en

European perspective on the ma ...... inical utility of tofacitinib.

@nl

type

Item

label

European perspective on the ma ...... inical utility of tofacitinib.

@en

European perspective on the ma ...... inical utility of tofacitinib.

@nl

prefLabel

European perspective on the ma ...... inical utility of tofacitinib.

@en

European perspective on the ma ...... inical utility of tofacitinib.

@nl

P1476

European perspective on the ma ...... inical utility of tofacitinib.

@en

P2093

Iwona Malinowska-Lipień

http://www.w3.org/2001/XMLSchema#string

Katarzyna Śladowska

http://www.w3.org/2001/XMLSchema#string

Maria Kózka

http://www.w3.org/2001/XMLSchema#string

Paweł Kawalec

http://www.w3.org/2001/XMLSchema#string

P2860

Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study

The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis

Lipid profile changes in patients with chronic inflammatory arthritis treated with biologic agents and tofacitinib in randomized clinical trials: a systematic review and meta-analysis

Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies

Biologic agents for rheumatoid arthritis--negotiating the NICE technology appraisals

Emerging Therapies for Rheumatoid Arthritis

The pathogenesis of rheumatoid arthritis

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

Evaluation of Real-World Experience with Tofacitinib Compared with Adalimumab, Etanercept, and Abatacept in RA Patients with 1 Previous Biologic DMARD: Data from a U.S. Administrative Claims Database.

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

P304

15-29

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S138677

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Tomasz Brzostek

P577

2017-12-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29317823

http://www.w3.org/2001/XMLSchema#string

P932

5743127

http://www.w3.org/2001/XMLSchema#string